Artia Global Partners as of March 31, 2024
Portfolio Holdings for Artia Global Partners
Artia Global Partners holds 49 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Eli Lilly & Co Put Put Option | 18.0 | $90M | 115k | 777.96 | |
| Novo-nordisk A S Adr (NVO) | 17.9 | $89M | 692k | 128.40 | |
| Eli Lilly & Co. (LLY) | 14.5 | $72M | 93k | 777.96 | |
| Merck & Co (MRK) | 10.1 | $50M | 379k | 131.95 | |
| Viking Therapeutics (VKTX) | 7.1 | $36M | 434k | 82.00 | |
| Abbvie (ABBV) | 3.3 | $17M | 91k | 182.10 | |
| Intra Cellular Therapies (ITCI) | 2.9 | $15M | 210k | 69.20 | |
| Argenx Se Sponsored Adr (ARGX) | 2.7 | $14M | 34k | 393.72 | |
| Astrazeneca Sponsored Adr (AZN) | 2.6 | $13M | 191k | 67.75 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.4 | $12M | 29k | 418.01 | |
| Axsome Therapeutics (AXSM) | 1.4 | $7.0M | 88k | 79.80 | |
| Ocular Therapeutix (OCUL) | 1.3 | $6.6M | 725k | 9.10 | |
| Cytokinetics Com New (CYTK) | 1.3 | $6.3M | 90k | 70.11 | |
| Neurocrine Biosciences (NBIX) | 1.2 | $6.2M | 45k | 137.92 | |
| Disc Medicine (IRON) | 1.1 | $5.4M | 87k | 62.26 | |
| Vaxcyte (PCVX) | 1.0 | $5.2M | 76k | 68.31 | |
| Apogee Therapeutics (APGE) | 0.8 | $4.1M | 62k | 66.45 | |
| Crinetics Pharmaceuticals In (CRNX) | 0.8 | $4.0M | 86k | 46.81 | |
| Protagonist Therapeutics (PTGX) | 0.7 | $3.6M | 124k | 28.93 | |
| Dyne Therapeutics (DYN) | 0.7 | $3.4M | 120k | 28.39 | |
| Insmed Com Par $.01 (INSM) | 0.6 | $3.2M | 118k | 27.13 | |
| Springworks Therapeutics (SWTX) | 0.5 | $2.7M | 54k | 49.22 | |
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.5 | $2.4M | 16k | 151.17 | |
| Ideaya Biosciences (IDYA) | 0.5 | $2.3M | 53k | 43.88 | |
| Merus N V (MRUS) | 0.5 | $2.3M | 50k | 45.03 | |
| Verona Pharma Sponsored Ads (VRNA) | 0.4 | $2.1M | 131k | 16.09 | |
| Alpine Immune Sciences | 0.4 | $2.0M | 52k | 39.64 | |
| Charles River Laboratories (CRL) | 0.4 | $1.9M | 6.9k | 270.95 | |
| Janux Therapeutics (JANX) | 0.4 | $1.8M | 48k | 37.65 | |
| Soleno Therapeutics (SLNO) | 0.4 | $1.8M | 41k | 42.80 | |
| Xenon Pharmaceuticals (XENE) | 0.3 | $1.7M | 40k | 43.05 | |
| Arvinas Ord (ARVN) | 0.3 | $1.7M | 40k | 41.28 | |
| Pliant Therapeutics (PLRX) | 0.3 | $1.5M | 100k | 14.90 | |
| Mereo Biopharma Group Spon Ads (MREO) | 0.3 | $1.4M | 421k | 3.30 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.3 | $1.3M | 54k | 23.65 | |
| Rapt Therapeutics (RAPT) | 0.2 | $1.2M | 137k | 8.98 | |
| Silence Therapeutics Ads (SLN) | 0.2 | $1.1M | 53k | 21.60 | |
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.2 | $1.1M | 52k | 20.67 | |
| Annexon (ANNX) | 0.2 | $1.1M | 148k | 7.17 | |
| Vera Therapeutics Cl A (VERA) | 0.2 | $1.0M | 24k | 43.12 | |
| Macrogenics (MGNX) | 0.2 | $942k | 64k | 14.72 | |
| Kura Oncology (KURA) | 0.2 | $842k | 40k | 21.33 | |
| Immunovant (IMVT) | 0.1 | $691k | 21k | 32.31 | |
| Biomea Fusion (BMEA) | 0.1 | $530k | 36k | 14.95 | |
| Larimar Therapeutics (LRMR) | 0.1 | $442k | 58k | 7.59 | |
| Madrigal Pharmaceuticals (MDGL) | 0.1 | $416k | 1.6k | 267.04 | |
| Effector Therapeutics Call Call Option | 0.1 | $360k | 25k | 14.39 | |
| Poseida Therapeutics I (PSTX) | 0.1 | $274k | 86k | 3.19 | |
| Gritstone Oncology Ord (GRTSQ) | 0.0 | $245k | 95k | 2.57 |
